Quercetin: Antiviral, Anti-Inflammatory, and Senolytic — What the Clinical Trials Show

Quercetin is one of the most abundant flavonoids in the human diet — present in onions, apples, capers, berries, broccoli, and green tea — and one of the most pharmacologically active. Unlike many polyphenols studied primarily in animal models, quercetin has accumulated a substantial body of human clinical trial evidence across antiviral activity, upper respiratory infection prevention, cancer prevention, and anti-aging. Its pharmacological breadth reflects a compound that acts on multiple molecular targets simultaneously rather than through a single pathway.

Antiviral Activity — The Mechanism

Quercetin's antiviral properties are among the most thoroughly characterised of any dietary compound. It inhibits multiple steps in the viral replication cycle:

• Viral protease inhibition: Quercetin directly inhibits 3CL protease (Mpro) — the main enzyme SARS-CoV-2 and other coronaviruses use for replication — as well as PLpro (papain-like protease) and NTPase/helicase. Multiple molecular docking studies and in vitro experiments confirm potent inhibitory activity against these viral targets
• ACE2 receptor interference: Quercetin reduces viral entry by interfering with the ACE2 receptor used by SARS-CoV-2 to enter host cells
• Zinc ionophore activity: Quercetin facilitates zinc transport across cell membranes. Inside cells, zinc directly inhibits RNA-dependent RNA polymerase (RdRp) — the viral enzyme that copies viral RNA. This ionophore function is why quercetin + zinc combinations have been studied for antiviral activity

Antiviral Clinical Evidence

COVID-19 RCT: Faster Viral Clearance (p=0.0004)

In a 100-patient randomised controlled trial (Di Pierro et al., King Edward Medical University), patients with early-stage COVID-19 received either standard care or standard care plus Quercetin Phytosome® (500mg, three times daily in week 1; twice daily in week 2). Results were significant: patients in the quercetin group cleared SARS-CoV-2 significantly faster (p=0.0004) and had significantly faster symptom resolution (p=0.0051). Serum LDH — an inflammatory damage marker — also improved significantly (p=0.0001). No adverse events were reported.

Upper Respiratory Infections: 36% Severity Reduction

A double-blind, placebo-controlled RCT in 1002 adults found that 1000mg quercetin daily for 12 weeks did not significantly reduce URTI incidence overall, but produced a significant 36% reduction in URTI severity (p=0.020) and a 31% reduction in total sick days (p=0.048) in adults over 40. This is an important distinction: quercetin appears to reduce how badly infections affect you rather than completely preventing them — consistent with its anti-inflammatory and viral replication-inhibiting mechanisms.

NLRP3 Inflammasome Suppression — The Anti-Inflammatory Core

Quercetin is one of the most potent natural inhibitors of the NLRP3 inflammasome — the intracellular multiprotein complex responsible for activating IL-1β and IL-18, the cytokines that drive cytokine storm in severe viral infections and chronic inflammatory conditions including atherosclerosis, type 2 diabetes, and neurodegenerative disease. NLRP3 inflammasome overactivation is central to severe COVID-19, and quercetin's ability to suppress it (via SIRT1/NLRP3 pathway modulation) is considered a primary mechanism for its benefit in early-stage severe viral illness.

Senolytic Activity — Anti-Aging Mechanism

One of quercetin's most significant and underappreciated properties is its senolytic activity — the ability to selectively kill senescent cells. Senescent "zombie" cells are cells that have stopped dividing but refuse to die, secreting a toxic cocktail of inflammatory cytokines (the senescence-associated secretory phenotype, SASP) that drives chronic inflammation, tissue dysfunction, and age-related disease. Quercetin (especially in combination with the drug dasatinib in research settings) has been identified as one of the most potent senolytic agents discovered — clearing senescent cells from tissue in animal models and preliminary human studies. This property directly connects quercetin to longevity and healthy aging beyond its antiviral and anti-inflammatory effects.

Cancer Prevention — FAP Trial Evidence

In the most significant cancer prevention RCT involving quercetin, a Phase II trial in familial adenomatous polyposis (FAP) patients — who typically develop hundreds of colorectal polyps — found that the combination of quercetin (20mg/day) with curcumin (480mg/day) for 6 months produced a 60% reduction in polyp number and a 51% reduction in polyp size. This remains one of the strongest human cancer prevention signals for any natural compound combination. The mechanism involves quercetin-driven Phase II enzyme induction, apoptosis in pre-cancerous cells, and synergistic anti-proliferative activity with curcumin.

Dosing Summary

• General antiviral/immune support: 500mg quercetin phytosome daily
• Acute viral illness: 500–1000mg Quercetin Phytosome twice daily for 1–2 weeks (matches positive RCT doses)
• Cancer prevention (with curcumin): 20mg quercetin + 480mg curcumin daily (FAP trial protocol)
• Senolytic protocol (intermittent): Some longevity researchers use 500–1000mg quercetin for 2–3 days/week rather than daily — intermittent senolytic dosing to allow senescent cell clearance cycles
• Enhance bioavailability: Take with Vitamin C (regenerates oxidised quercetin and provides synergistic antiviral effects) and with food containing fat